Microbia Life Sciences Offers Compelling Long-Term Opportunity -- Market Talk

Dow Jones02-07

0058 GMT - Microbia Life Sciences looks undervalued to Morgans analyst Iain Wilkie, who sees it benefiting from healthcare professionals' increasing awareness of the importance of gut health. Initiating coverage of the stock with a speculative buy rating, Wilkie tells clients in a note that he likes the look of the global diagnostic partnerships established by Microbia, which specializes in gut-health testing and therapeutic development. ASX-listed Sonic Healthcare is a major shareholder. Microbia offers a compelling opportunity for long-term investors as it progresses clinical-stage drug development and the role of gut microbiome across a range of conditions is better understood, he reckons. Morgans places a A$0.35 target price on the stock, which is flat at A$0.165. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

February 06, 2024 19:58 ET (00:58 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2409254541?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-02-07 08:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2409254541","market":"sh","top_or_hot":-1,"title":"Microbia Life Sciences Offers Compelling Long-Term Opportunity -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0058 GMT - Microbia Life Sciences looks undervalued to Morgans analyst Iain Wilkie, who sees it benefiting from healthcare professionals' increasing awareness of the importance of gut health. Initiating coverage of the stock with a speculative buy rating, Wilkie tells clients in a note that he likes the look of the global diagnostic partnerships established by Microbia, which specializes in gut-health testing and therapeutic development. ASX-listed Sonic Healthcare is a major shareholder. Microbia offers a compelling opportunity for long-term investors as it progresses clinical-stage drug development and the role of gut microbiome across a range of conditions is better understood, he reckons. Morgans places a A$0.35 target price on the stock, which is flat at A$0.165. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 06, 2024 19:58 ET (00:58 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Microbia Life Sciences Offers Compelling Long-Term Opportunity -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicrobia Life Sciences Offers Compelling Long-Term Opportunity -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-02-07 08:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>0058 GMT - Microbia Life Sciences looks undervalued to Morgans analyst Iain Wilkie, who sees it benefiting from healthcare professionals' increasing awareness of the importance of gut health. ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7124","symbol_name":"保健护理服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2409254541","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2409254541","pubTimestamp":1707267480,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0058 GMT - Microbia Life Sciences looks undervalued to Morgans analyst Iain Wilkie, who sees it benefiting from healthcare professionals' increasing awareness of the importance of gut health. Initiating coverage of the stock with a speculative buy rating, Wilkie tells clients in a note that he likes the look of the global diagnostic partnerships established by Microbia, which specializes in gut-health testing and therapeutic development. ASX-listed Sonic Healthcare is a major shareholder. Microbia offers a compelling opportunity for long-term investors as it progresses clinical-stage drug development and the role of gut microbiome across a range of conditions is better understood, he reckons. Morgans places a A$0.35 target price on the stock, which is flat at A$0.165. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7124":"保健护理服务","MAP.AU":"MICROBA LIFE SCIENCES LTD"},"translate_title":"微生物生命科学提供引人注目的长期机遇——市场谈资","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MAP.AU":0.9},"content_text":"0058 GMT - Microbia Life Sciences looks undervalued to Morgans analyst Iain Wilkie, who sees it benefiting from healthcare professionals' increasing awareness of the importance of gut health. Initiating coverage of the stock with a speculative buy rating, Wilkie tells clients in a note that he likes the look of the global diagnostic partnerships established by Microbia, which specializes in gut-health testing and therapeutic development. ASX-listed Sonic Healthcare is a major shareholder. Microbia offers a compelling opportunity for long-term investors as it progresses clinical-stage drug development and the role of gut microbiome across a range of conditions is better understood, he reckons. Morgans places a A$0.35 target price on the stock, which is flat at A$0.165. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 06, 2024 19:58 ET (00:58 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2409254541"}